This page in English

Jonas Halfvarson

Befattning: Professor Organisation: Institutionen för medicinska vetenskaper


Telefon: 0738 082361

Rum: X2212

Jonas Halfvarson

Om Jonas Halfvarson

In Sweden more than 61 000 individuals are affected by inflammatory bowel disease (IBD), including the predominant forms Crohn’s disease and ulcerative colitis. In the absence of a prevention strategies and curative treatment, the disease has a major impact on many affected individuals, including life-long medication, hospitalizations, recurring sick-leaves, and often a need for surgical intervention. IBD has a high and escalating incidence throughout the world, especially among teenagers and elderly, reflecting the strategic importance for the society at large, both from patient and health care perspectives. My research goal is to improve the healthcare for individuals affected by IBD and thereby increasing their quality of life. I aim to accomplish this by identifying biomarkers that can be used to diagnose the diseases (diagnostic biomarkers) and to foresee who will progress to a severe disease status (prognostic biomarkers). Individuals who will progress to a severe disease status are in need of treatment with biologics already at diagnosis. Therefore, I aim to identify biomarkers that can be used to foresee who will respond from a specific treatment (predictive biomarkers) and who will benefit from taking the drug over a longer period of time (prognostic biomarkers).



Artiklar i tidskrifter |  Artiklar, forskningsöversikter |  Kapitel i böcker, del av antologier |  Konferensbidrag |  Manuskript | 

Artiklar i tidskrifter

Artiklar, forskningsöversikter

Kapitel i böcker, del av antologier